State Errors to Blame for Post-Pandemic Medicaid Disenrollments & More

Many Post-Pandemic Medicaid Disenrollments May Be Due to State Errors

Federal officials have uncovered significant problems with the systems and procedures states have been employing to “unwind” Medicaid coverage protections put in place during the pandemic. A senior official at the Centers for Medicare and Medicaid Services said many states have been conducting automatic or “ex parte” renewals based on state databases to determine whether residents are still eligible for Medicaid coverage, sending out renewal forms and disenrolling anyone who doesn’t return them. (NEW YORK TIMES)

Biden Administration Announces First Drugs for Medicare Price Negotiation

The Centers for Medicare and Medicaid Services announced the first 10 medications selected for price negotiations with Medicare in accordance with the Inflation Reduction Act, signed by President Biden in August 2022. CMS prioritized drugs that account for the most Medicare spending and came on the market years ago but face little competition. (NEW YORK TIMES)

Govs Call for Congressional Action on Prescription Drug Shortages

A group of 11 governors, led by South Dakota Gov. Kristi Noem (R), sent a letter to congressional leaders urging them to take action to address shortages of prescription drugs. Noting that 80% of the active ingredients in prescription drugs come from other countries, mainly China and India, the governors called for policies to "increase diversity in the manufacturing of generic medications with regards to both raw materials and final manufacturing," require greater transparency from the FDA regarding shortages and relax the guidance for medication expiration dates to extend its shelf life. (CENTER SQUARE)

—Compiled by SNCJ Managing Editor KOREY CLARK

Please visit our webpage to connect with a State Net® representative and learn how the State Net legislative and regulatory tracking solution can help you identify, track, analyze and report on relevant legislative and regulatory developments.